- Home
- NAUT vs RCS Comparison
NAUT vs RCS Comparison
Compare NAUT & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAUT | RCS |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.4M | 308.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAUT | RCS |
|---|---|---|
| Price | $1.93 | $6.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 275.8K | 141.1K |
| Earning Date | 10-28-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $4.51 |
| 52 Week High | $2.54 | $6.31 |
Technical Indicators
Market Signals| Indicator | NAUT | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 40.75 |
| Support Level | $1.78 | $6.64 |
| Resistance Level | $2.12 | $6.76 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 37.50 | 15.00 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.